 |
19 Diseases |  |
5 Trials |
|
5 Trials |  |
30 News |  |
- Allergen immunotherapy / Stallergenes, Staloral (allergy immunotherapy sublingual) / Stallergenes
Prospective, pilot, phase 1 study of iPUMP (Innovation Hub) - Apr 21, 2024 - Abstract #EAACI2024EAACI_1760;
It is easy to use and the functions in the connected device and app. can be consulted by patients to monitor their own compliance.
- ||||| Staloral (allergy immunotherapy sublingual) / Stallergenes
Enrollment closed, Trial completion date, Trial primary completion date: YOBI: Safety and Efficacy of STALORAL (clinicaltrials.gov) - Apr 18, 2024
P3, N=699, Active, not recruiting, Sponsor: Stallergenes Greer
can be consulted by patients to monitor their own compliance. Not yet recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Nov 2025 | Trial primary completion date: May 2024 --> Jul 2025
- |||||||||| Staloral (allergy immunotherapy sublingual) / Stallergenes
New P3 trial: YOBI: Safety and Efficacy of STALORAL (clinicaltrials.gov) - Dec 29, 2022
P3, N=699, Not yet recruiting, Sponsor: Stallergenes Greer
- || Staloral (allergy immunotherapy sublingual) / Stallergenes
Clinical, Journal: Comparison of Sublingual Immunotherapy in Patients With Allergic Rhinitis Sensitive to House Dust Mites in Korea. (Pubmed Central) - Dec 16, 2021
In conclusion, the improvements in symptom score and medication scores were not significant different between 2 SLIT medications at 1 year. LAIS was more compliant, less side effects and Staloral has shown increased satisfaction rate and IgG4 level.
- || Staloral (allergy immunotherapy sublingual) / Stallergenes
Clinical, Observational data, Journal: Relevant Patient Benefit of Sublingual Immunotherapy with Birch Pollen Allergen Extract in Allergic Rhinitis: An Open, Prospective, Non-Interventional Study. (Pubmed Central) - Feb 23, 2021
LAIS was more compliant, less side effects and Staloral has shown increased satisfaction rate and IgG4 level. After 1 year of birch pollen SLIT treatment, patients reported considerable benefit, mainly due to a reduction of physical symptoms and treatment burden.
- | Staloral (allergy immunotherapy sublingual) / Stallergenes
Observational data, Retrospective data, Journal: A Retrospective Nationwide Non-Interventional Study of an Aqueous Sublingual Immunotherapy Formulation Administered with a 200-µL Dosing Pump. (Pubmed Central) - Feb 17, 2021
After 1 year of birch pollen SLIT treatment, patients reported considerable benefit, mainly due to a reduction of physical symptoms and treatment burden. Administration of 300 index of reactivity SLIT with a 200-µL dosing pump is safe, well tolerated and associated with good levels of patient satisfaction.
- || Staloral (allergy immunotherapy sublingual) / Stallergenes
Clinical, Clinical data, Journal: Comparative analysis of sublingual immunotherapy medicines for adherence and clinical outcomes. (Pubmed Central) - Oct 16, 2020
Administration of 300 index of reactivity SLIT with a 200-µL dosing pump is safe, well tolerated and associated with good levels of patient satisfaction. Although all three SLIT medicines are effective in improving AR symptoms, the adherence to SLIT assessed in accordance with dropout rate was the lowest in the Staloral.
- || Review, Journal: Allergy immunotherapies for allergic rhinitis: systematic review and assessment of evolving quality. (Pubmed Central) - Jun 15, 2020
Conclusions. When as-sessing grass AIT, it is important to focus not only on endpoints but also on the quality of evidence.
- Staloral (allergy immunotherapy sublingual) / Stallergenes
[VIRTUAL] Food allergies in children with birch pollen allergy and various profiles of sensitization to pollen components () - May 19, 2020 - Abstract #EAACI2020EAACI_597;
We found an early onset of symptoms of plant food allergy in children with hay fever. The efficiency of SLIT was higher in patients with monosensitization to Bet v1 in relation to both clinical symptoms of hay fever and PFAS.
- | Staloral (allergy immunotherapy sublingual) / Stallergenes, Grazax (timothy grass pollen allergen extract tablet) - ALK / Abello
New P4 trial, IO biomarker: The effect of allergen and virus on tonsillar cell function Allergeenin ja viruksen vaikutus nielurisan solujen toimintaan (EUDRACT) - Jun 10, 2013
P4, N=120, Ongoing, Sponsor: Turku University Hospital
- Staloral (allergy immunotherapy sublingual) / Stallergenes
Trial completion, IO biomarker: A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy (clinicaltrials.gov) - Feb 10, 2013
P4, N=30, Completed, Sponsor: Bayside Health
The efficiency of SLIT was higher in patients with monosensitization to Bet v1 in relation to both clinical symptoms of hay fever and PFAS. Not yet recruiting --> Completed
- | Staloral (allergy immunotherapy sublingual) / Stallergenes
New P4 trial, IO biomarker: POLET: POLlinosis and Exhaled Breath Temperature (clinicaltrials.gov) - Feb 5, 2013
P4, N=60, Active, not recruiting, Sponsor: Prof. Todor Popov
- |||||||||| Allergen immunotherapy / Stallergenes
New P3 trial, IO biomarker: Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis (clinicaltrials.gov) - Nov 19, 2012
P3, N=574, Completed, Sponsor: Stallergenes
- | Staloral (allergy immunotherapy sublingual) / Stallergenes
New P4 trial: House Dust Mite SLIT in Elderly Patients (clinicaltrials.gov) - May 16, 2012
P4, N=111, Completed, Sponsor: Medical University of Silesia
- ||||| Allergen immunotherapy / Stallergenes, Staloral (allergy immunotherapy sublingual) / Stallergenes
Enrollment change: A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites (clinicaltrials.gov) - Oct 10, 2011
P3, N=484, Completed, Sponsor: Stallergenes
Not yet recruiting --> Completed N=700 --> 484
- ||||||| Allergen immunotherapy / Stallergenes, Staloral (allergy immunotherapy sublingual) / Stallergenes
Trial completion: A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites (clinicaltrials.gov) - Oct 10, 2011
P3, N=484, Completed, Sponsor: Stallergenes
N=700 --> 484 Active, not recruiting --> Completed
- Staloral (allergy immunotherapy sublingual) / Stallergenes
Enrollment change: Comparison of Effectiveness and Safety of Sublingual Immunotherapy in Children With Allergic Rhinitis (clinicaltrials.gov) - Aug 17, 2011
P4, N=60, Completed, Sponsor: Medical Universtity of Lodz
Active, not recruiting --> Completed N=90 --> 60
- Staloral (allergy immunotherapy sublingual) / Stallergenes
Trial completion: Comparison of Effectiveness and Safety of Sublingual Immunotherapy in Children With Allergic Rhinitis (clinicaltrials.gov) - Aug 17, 2011
P4, N=60, Completed, Sponsor: Medical Universtity of Lodz
N=90 --> 60 Active, not recruiting --> Completed